28-Feb-2025
No headlines found.
Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call
Globe Newswire (Fri, 21-Feb 8:30 AM ET)
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 7-Feb 4:30 PM ET)
Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock
Globe Newswire (Fri, 7-Feb 7:54 AM ET)
Neuronetics Announces Launch of Underwritten Public Offering of Common Stock
Globe Newswire (Thu, 6-Feb 4:23 PM ET)
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression
Globe Newswire (Wed, 29-Jan 8:31 AM ET)
Neuronetics Provides Business Update and Issues 2025 Guidance
Globe Newswire (Mon, 13-Jan 8:00 AM ET)
Neuronetics and Greenbrook TMS Announce Closing of Transaction
Globe Newswire (Tue, 10-Dec 10:00 AM ET)
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Neuronetics trades on the NASDAQ stock market under the symbol STIM.
As of February 28, 2025, STIM stock price declined to $4.25 with 999,063 million shares trading.
STIM has a market cap of $270.52 million. This is considered a Small Cap stock.
Last quarter Neuronetics reported $19 million in Revenue and -$.29 earnings per share. This fell short of revenue expectation by $-600,000 and missed earnings estimates by -$.06.
In the last 3 years, STIM traded as high as $6.95 and as low as $.52.
The top ETF exchange traded funds that STIM belongs to (by Net Assets): VTI, VXF, PSIL, IWC.
STIM has outperformed the market in the last year with a price return of +43.1% while the SPY ETF gained +18.8%. STIM has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +341.3% and -2.5%, respectively, while the SPY returned -0.4% and -2.5%, respectively.
STIM support price is $3.87 and resistance is $4.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STIM shares will trade within this expected range on the day.